Directed share issue in BICO Group AB (SE) — SEK 2.0 billion

Carnegie acted as joint global co-ordnatior and joint bookrunner in the directed share issue of 4,250,000 new shares of serie B at a subscription price of SEK 480 per share. Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.
October 2021.